Teva- Pharmaceutical Industries Overview
Teva- Pharmaceutical Industries Target Price
Analysts' average 12-month price target for Teva- Pharmaceutical Industries is $48.
Get informed when a big investor buys or sells
+ FollowShare Price
$42.4
Average Target Price
$47.50
12% upside
12% upside8 analysts in the last 4 months
High: $54 | Low: $42
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-11-04 | H.C. WainwrightDouglas Tsao | $54 | 27.4% upside |  |
| 2026-10-15 | BarclaysGlen Santangelo | $47 | 10.8% upside | |
| 2026-10-12 | Raymond James | $50 | 17.9% upside | |
| 2026-09-23 | OppenheimerLes Sulewski | $50 | 17.9% upside | |
| 2026-09-09 | Leerink Partners | $45 | 6.1% upside | |
| 2026-09-04 | UBSAshwani Verma | $48 | 13.2% upside | |
| 2026-08-12 | Barclays | $42 |  0.9% downside | |
| 2026-07-28 | Piper SandlerDavid Amsellem | $44 | 3.8% upside | |
| 2026-05-06 | Barclays | $40 | 5.7% downside | |
| 2026-04-30 | Piper Sandler | $42 | 0.9% downside | |
| 2026-04-30 | UBS | $42 | 0.9% downside | |
| 2026-03-04 | Piper SandlerDavid Amsellem | $41 | 3.3% downside | |
| 2026-01-30 | BarclaysGlen Santangelo | $38 | 10.4% downside | |
| 2026-01-29 | Scotiabank | $40 | 5.7% downside | |
| 2026-01-07 | Truist Financial | $36 | 15.1% downside | |
| 2026-01-06 | Jefferies | $40 | 5.7% downside | |
| 2025-12-22 | Piper Sandler | $40 | 5.7% downside | |
| 2025-12-18 | Goldman Sachs | $35 | 17.5% downside | |
| 2025-12-08 | Barclays | $35 | 17.5% downside | |
| 2025-12-04 | Scotiabank | $35 | 17.5% downside | |
| 2025-11-06 | Goldman SachsMatt Dellatorre | $28 | 34% downside | |
| 2024-12-18 | UBSAshwani Verma | $28 | 34% downside | |
| 2024-12-18 | BarclaysBalaji Prasad | $28 | 34% downside | |
| 2024-10-23 | BarclaysBalaji Prasad | $25 | 41% downside | |
| 2024-10-01 | Bank of America SecuritiesJason Gerberry | $22 | 48.1% downside | |
| 2024-09-03 | UBSAshwani Verma | $26 | 38.7% downside | |
| 2024-08-28 | Piper SandlerDavid Amsellem | $23 | 45.8% downside | |
| 2024-08-01 | BarclaysBalaji Prasad | $22 | 48.1% downside | |
| 2024-07-10 | Argus ResearchJasper Hellweg | $20 | 52.8% downside | |
| 2024-07-10 | UBSAshwani Verma | $24 | 43.4% downside | |
| 2024-06-05 | BarclaysBalaji Prasad | $21 | 50.5% downside | |
| 2024-05-23 | BarclaysBalaji Prasad | $20 | 52.8% downside | |
| 2024-05-13 | Piper SandlerDavid Amsellem | $20 | 52.8% downside | |
| 2024-02-12 | Piper SandlerDavid Amsellem | $19 | 55.2% downside | |
| 2024-01-23 | JefferiesGlen Santangelo | $14 | 67% downside | |
| 2022-11-14 | J.P. Morgan | $10 | 76.4% downside | |
| 2022-06-13 | UBSAshwani Verma | $10 | 76.4% downside | |
| 2022-05-04 | Piper Sandler | $7 | 83.5% downside | |
| 2022-04-20 | BarclaysBalaji Prasad | $13 | 69.3% downside | |